Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

PHASE3CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

March 16, 2018

Study Completion Date

March 16, 2018

Conditions
HypercholesterolemiaAtherosclerotic Cardiovascular DiseaseStatin Adverse Reaction
Interventions
DRUG

bempedoic acid

bempedoic acid 180 mg tablet

OTHER

placebo

Matching placebo tablet

Trial Locations (67)

Unknown

Gilbert

Anaheim

Long Beach

Sacramento

Santa Ana

Torrance

Ventura

Hamden

Daytona Beach

Fort Lauderdale

Site 1, Miami

Site 2, Miami

Orlando

West Palm Beach

Atlanta

Savannah

Meridian

Evanston

Evansville

Iowa City

Waterloo

Monroe

Slidell

Tupelo

Lincoln

Somerset

Binghamton

Endwell

New Windsor

Greensboro

Morganton

Mount Airy

Columbus

Marion

Maumee

Oklahoma City

Beaver

Langhorne

Cumberland

Anderson

Summerville

Jackson

Knoxville

Memphis

Amarillo

Site 1, Dallas

Site 2, Dallas

Houston

San Antonio

Clinton

Hampton

Kenosha

Brossard

Chicoutimi

Gatineau

London

Longueuil

Mirabel

Montreal

Newmarket

Oakville

Peterborough

Pointe-Claire

Saint-Jérôme

Sarnia

Toronto

Victoriaville

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY